Teladoc (NYSE:TDOC) had its target price lifted by equities researchers at SunTrust Banks to $100.00 in a research note issued on Monday, The Fly reports. The firm presently has a “buy” rating on the health services provider’s stock. SunTrust Banks’ price objective indicates a potential upside of 23.76% from the stock’s current price.
TDOC has been the topic of a number of other reports. Oppenheimer boosted their price objective on shares of Teladoc from $59.00 to $68.00 and gave the company an “outperform” rating in a research report on Thursday, August 2nd. Craig Hallum raised shares of Teladoc from a “hold” rating to a “buy” rating in a research report on Tuesday, June 5th. Cantor Fitzgerald boosted their price objective on shares of Teladoc from $35.00 to $50.00 and gave the company a “neutral” rating in a research report on Tuesday, June 5th. Wells Fargo & Co reissued a “buy” rating and set a $70.00 price objective on shares of Teladoc in a research report on Thursday, August 2nd. Finally, KeyCorp boosted their price objective on shares of Teladoc from $70.00 to $74.00 and gave the company an “overweight” rating in a research report on Thursday, August 2nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $67.80.
Shares of NYSE TDOC traded up $2.70 during mid-day trading on Monday, hitting $80.80. The stock had a trading volume of 12,598 shares, compared to its average volume of 1,062,756. The company has a quick ratio of 3.14, a current ratio of 3.14 and a debt-to-equity ratio of 0.58. Teladoc has a 1 year low of $27.30 and a 1 year high of $79.64. The company has a market cap of $5.43 billion, a price-to-earnings ratio of -48.85 and a beta of 0.57.
In related news, SVP Andrew Turitz sold 13,821 shares of the company’s stock in a transaction dated Tuesday, July 3rd. The shares were sold at an average price of $59.43, for a total value of $821,382.03. Following the transaction, the senior vice president now owns 9,378 shares in the company, valued at approximately $557,334.54. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Lewis Levy sold 1,284 shares of the company’s stock in a transaction dated Monday, September 17th. The stock was sold at an average price of $77.00, for a total transaction of $98,868.00. Following the completion of the transaction, the insider now owns 1,284 shares in the company, valued at approximately $98,868. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 268,781 shares of company stock worth $18,083,387. Company insiders own 3.95% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the stock. We Are One Seven LLC lifted its stake in Teladoc by 241.1% during the 1st quarter. We Are One Seven LLC now owns 2,845 shares of the health services provider’s stock valued at $115,000 after acquiring an additional 2,011 shares during the period. Garner Asset Management Corp bought a new position in Teladoc during the 2nd quarter valued at about $200,000. Pier 88 Investment Partners LLC bought a new position in Teladoc during the 2nd quarter valued at about $201,000. Aperio Group LLC bought a new position in Teladoc during the 2nd quarter valued at about $201,000. Finally, California Public Employees Retirement System bought a new position in Teladoc during the 2nd quarter valued at about $203,000.
Teladoc Company Profile
Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Read More: Moving Average (MA)
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.